Halozyme Therapeutics Inc (HALO)
44.32
+0.97
(+2.24%)
USD |
NASDAQ |
May 31, 16:00
44.32
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Total Liabilities (Quarterly): 1.664B for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.664B |
December 31, 2023 | 1.649B |
September 30, 2023 | 1.643B |
June 30, 2023 | 1.659B |
March 31, 2023 | 1.634B |
December 31, 2022 | 1.672B |
September 30, 2022 | 1.768B |
June 30, 2022 | 1.488B |
March 31, 2022 | 901.99M |
December 31, 2021 | 907.48M |
September 30, 2021 | 903.75M |
June 30, 2021 | 906.12M |
March 31, 2021 | 898.99M |
December 31, 2020 | 428.88M |
September 30, 2020 | 425.04M |
June 30, 2020 | 421.42M |
March 31, 2020 | 434.31M |
December 31, 2019 | 474.11M |
September 30, 2019 | 125.00M |
June 30, 2019 | 157.78M |
March 31, 2019 | 169.06M |
December 31, 2018 | 191.36M |
September 30, 2018 | 204.77M |
June 30, 2018 | 219.83M |
March 31, 2018 | 230.40M |
Date | Value |
---|---|
December 31, 2017 | 311.58M |
September 30, 2017 | 284.76M |
June 30, 2017 | 286.62M |
March 31, 2017 | 285.27M |
December 31, 2016 | 294.00M |
September 30, 2016 | 294.49M |
June 30, 2016 | 286.21M |
March 31, 2016 | 279.62M |
December 31, 2015 | 138.79M |
September 30, 2015 | 126.94M |
June 30, 2015 | 123.82M |
March 31, 2015 | 121.58M |
December 31, 2014 | 124.62M |
September 30, 2014 | 124.69M |
June 30, 2014 | 126.75M |
March 31, 2014 | 130.94M |
December 31, 2013 | 121.78M |
September 30, 2013 | 113.63M |
June 30, 2013 | 96.24M |
March 31, 2013 | 85.19M |
December 31, 2012 | 85.87M |
September 30, 2012 | 56.79M |
June 30, 2012 | 52.51M |
March 31, 2012 | 53.66M |
December 31, 2011 | 54.86M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
125.00M
Minimum
Sep 2019
1.768B
Maximum
Sep 2022
1.008B
Average
904.93M
Median
Total Liabilities (Quarterly) Benchmarks
Novavax Inc | 2.221B |
Denali Therapeutics Inc | 125.62M |
AIM ImmunoTech Inc | 11.36M |
Protalix BioTherapeutics Inc | 60.04M |
Armata Pharmaceuticals Inc | 176.87M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 1.842B |
Shareholders Equity (Quarterly) | 177.81M |
Debt to Equity Ratio | 8.441 |
Current Ratio | 6.636 |
Net Debt Paydown Yield | 0.02% |